483
Samsung Biologics Co., Ltd.FDA 483 - Samsung Biologics Co., Ltd.
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Samsung Biologics Co., Ltd. in Incheon, Korea, revealed significant deficiencies across multiple areas of their drug manufacturing operations. Key issues included inadequate data integrity controls in the MSAT laboratory, failures to follow written procedures for aseptic processing, and a deficient Quality Unit. The inspection also cited problems with equipment revalidation and facility maintenance, indicating a broad scope of non-compliance.
- Company
- Samsung Biologics Co., Ltd.
- Product Type
- Drugs
Open in Dashboard
ID · f77a8fa0-5e1a-49af-b52c-92b0e5e25865